Ikena Oncology Statistics
Share Statistics
Ikena Oncology has 48.26M shares outstanding. The number of shares has increased by 10.09% in one year.
| Shares Outstanding | 48.26M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 27.31M |
| Failed to Deliver (FTD) Shares | 2.55K |
| FTD / Avg. Volume | 4.21% |
Short Selling Information
The latest short interest is 129.88K, so 0.27% of the outstanding shares have been sold short.
| Short Interest | 129.88K |
| Short % of Shares Out | 0.27% |
| Short % of Float | 0.62% |
| Short Ratio (days to cover) | 3.02 |
Valuation Ratios
The PE ratio is -1.21 and the forward PE ratio is -2.07.
| PE Ratio | -1.21 |
| Forward PE | -2.07 |
| PS Ratio | 8.98 |
| Forward PS | 31.8 |
| PB Ratio | 0.48 |
| P/FCF Ratio | -1.03 |
| PEG Ratio | n/a |
Enterprise Valuation
Ikena Oncology Inc. has an Enterprise Value (EV) of 92.96M.
| EV / Earnings | -1.36 |
| EV / Sales | 10.15 |
| EV / EBITDA | -1.25 |
| EV / EBIT | -1.23 |
| EV / FCF | -1.16 |
Financial Position
The company has a current ratio of 12.58, with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.58 |
| Quick Ratio | 12.58 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 2.05 |
| Cash Flow / Debt | -22.41 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.4% and return on capital (ROIC) is -41.68%.
| Return on Equity (ROE) | -0.4% |
| Return on Assets (ROA) | -0.35% |
| Return on Capital (ROIC) | -41.68% |
| Revenue Per Employee | 654.29K |
| Profits Per Employee | -4.87M |
| Employee Count | 14 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -162.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -16.24% in the last 52 weeks. The beta is 0.48, so Ikena Oncology 's price volatility has been higher than the market average.
| Beta | 0.48 |
| 52-Week Price Change | -16.24% |
| 50-Day Moving Average | 1.71 |
| 200-Day Moving Average | 1.6 |
| Relative Strength Index (RSI) | 38.95 |
| Average Volume (20 Days) | 60.58K |
Income Statement
In the last 12 months, Ikena Oncology had revenue of $9.16M and earned -$68.17M in profits. Earnings per share was $-1.63.
| Revenue | 9.16M |
| Gross Profit | 8.14M |
| Operating Income | -75.42M |
| Net Income | -68.17M |
| EBITDA | -74.40M |
| EBIT | -75.42M |
| Earnings Per Share (EPS) | -1.63 |
Balance Sheet
The company has $119.89M in cash and $10.74M in debt, giving a net cash position of $109.16M.
| Cash & Cash Equivalents | 119.89M |
| Total Debt | 10.74M |
| Net Cash | 109.16M |
| Retained Earnings | -282.38M |
| Total Assets | 148.99M |
| Working Capital | 132.29M |
Cash Flow
In the last 12 months, operating cash flow was -$79.74M and capital expenditures -$414.00K, giving a free cash flow of -$80.16M.
| Operating Cash Flow | -79.74M |
| Capital Expenditures | -414.00K |
| Free Cash Flow | -80.16M |
| FCF Per Share | -1.92 |
Margins
Gross margin is 88.86%, with operating and profit margins of -823.33% and -744.17%.
| Gross Margin | 88.86% |
| Operating Margin | -823.33% |
| Pretax Margin | -745.94% |
| Profit Margin | -744.17% |
| EBITDA Margin | -812.19% |
| EBIT Margin | -823.33% |
| FCF Margin | -875.08% |
Dividends & Yields
IKNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -98.79% |
| FCF Yield | -100.97% |
Analyst Forecast
The average price target for IKNA is $3, which is 81.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 81.8% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -0.13 |
| Piotroski F-Score | 1 |